Mechanistic and Clinical Aspects of Benign Thyroid Disease
Presenter: Ricardo Correa, MD, EdD, FACP, FACE, FAPCR, FACMQ (University of Arizona College of Medicine Phoenix)
Relationship: Commercial Interest(s)
  Owner/Co-Owner: Founder and Consultant - VASARAGEN, Vasaragen.
  Grant Recipient: Sandoz.
  Other: Bayer, Inc.

Outcomes and Predictors of 30-day Readmission for Hyperthyroidism: A Nationwide Study
Presenter: Oluwatomi Adeoti, MD, MPH (Boston University School of Medicine/Boston Medical Center, Boston, MA, USA)
No relevant financial relationships

Outcomes and Predictors of 30-day Readmission for Hyperthyroidism: A Nationwide Study
Presenter: Michael Salim, MD (Mount Sinai Hospital, 1500 S. Fairfield, Chicago, IL, USA)
No relevant financial relationships

Outcomes and Predictors of 30-day Readmission for Hyperthyroidism: A Nationwide Study
Presenter: Asim Kichloo, MD (Central Michigan University College of Medicine, Saginaw, MI, USA)
No relevant financial relationships

Outcomes and Predictors of 30-day Readmission for Hyperthyroidism: A Nationwide Study
Presenter: Hafeez Shaka, MD (John H. Stroger Jr. Hospital Cook County, Chicago, IL, USA)
No relevant financial relationships

Mechanistic and Clinical Aspects of Benign Thyroid Disease
Presenter: Martha Katherine Huayllas, MD (Hospital Brigadeiro)
No relevant financial relationships

Mechanistic and clinical aspects of benign thyroid disease
Presenter: Dr. Angela Leung, MD, MSc (UCLA David Geffen School of Medicine)
No relevant financial relationships

Mechanistic and clinical aspects of benign thyroid disease
Presenter: Dr. Simon Pearce, MBBS,FRCP,MD (Newcastle University)
No relevant financial relationships

Liquid Levothyroxine (L-T4) Maintains More Stable TSH Levels in Hypothyroid Patients, Than Tablet L-T4
Presenter: Prof Poupak Fallahi, MD (University of Pisa, Department of Translational Research of New Technologies in Medicine and Surgery)
No relevant financial relationships

Liquid Levothyroxine (L-T4) Maintains More Stable TSH Levels in Hypothyroid Patients, Than Tablet L-T4
Presenter: Silvia Martina Ferrari, MSc (University of Pisa, Department of Clinical and Experimental Medicine)
No relevant financial relationships

Liquid Levothyroxine (L-T4) Maintains More Stable TSH Levels in Hypothyroid Patients, Than Tablet L-T4
Presenter: Giusy Elia, MSc (University of Pisa, Department of Surgical, Medical and Molecular Pathology and Critical Area)
No relevant financial relationships

Liquid Levothyroxine (L-T4) Maintains More Stable TSH Levels in Hypothyroid Patients, Than Tablet L-T4
Presenter: Francesca Ragusa, MSc (University of Pisa, Department of Surgical, Medical and Molecular Pathology and Critical Area)
No relevant financial relationships

Liquid Levothyroxine (L-T4) Maintains More Stable TSH Levels in Hypothyroid Patients, Than Tablet L-T4
Presenter: Sabrina Rosaria Paparo, MSc (University of Pisa, Department of Surgical, Medical and Molecular Pathology and Critical Area)
No relevant financial relationships

Liquid Levothyroxine (L-T4) Maintains More Stable TSH Levels in Hypothyroid Patients, Than Tablet L-T4
Presenter: Eugenia Balestri, MSc (University of Pisa, Department of Surgical, Medical and Molecular Pathology and Critical Area)
No relevant financial relationships

Liquid Levothyroxine (L-T4) Maintains More Stable TSH Levels in Hypothyroid Patients, Than Tablet L-T4
Presenter: Chiara Botrini, MSc (University of Pisa, Department of Surgical, Medical and Molecular Pathology and Critical Area)
No relevant financial relationships

Liquid Levothyroxine (L-T4) Maintains More Stable TSH Levels in Hypothyroid Patients, Than Tablet L-T4
Presenter: Armando Patrizio, MD (Azienda Ospedaliero-Universitaria Pisana, Department of Emergency Medicine)
No relevant financial relationships

Liquid Levothyroxine (L-T4) Maintains More Stable TSH Levels in Hypothyroid Patients, Than Tablet L-T4
Presenter: Valeria Mazzi, MD (University of Pisa, Department of Surgical, Medical and Molecular Pathology and Critical Area)
No relevant financial relationships

Liquid Levothyroxine (L-T4) Maintains More Stable TSH Levels in Hypothyroid Patients, Than Tablet L-T4
Presenter: Dr. Alessandro Antonelli, MD, Prof (University of Pisa, Department of Surgical, Medical and Molecular Pathology and Critical Area)
No relevant financial relationships

RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies
Presenter: Joshua Stokar, MD (Hadassah Medical Center & Hebrew University of Jerusalem)
No relevant financial relationships

RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies
Presenter: Rena Pollack, MD (Hadassah-Hebrew University Medical Center)
No relevant financial relationships

RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies
Presenter: Natan Lishinsky, BMSc (Hebrew University, The Faculty of Medicine)
No relevant financial relationships

RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies
Presenter: Irina Gurt, PhD (Hadassah-Hebrew University Medical Center)
No relevant financial relationships

RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies
Presenter: Naomi Kaisar-Iluz, MA (Hadassah-Hebrew University Medical Center)
No relevant financial relationships

RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies
Presenter: Merav E Shaul, PhD (Hadassah-Hebrew University Medical Center)
No relevant financial relationships

RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies
Presenter: Zvi G Fridlender, MD (Hadassah-Hebrew University Medical Center)
No relevant financial relationships

RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies
Presenter: Rivka Dresner-Pollak, MD (Hadassah-Hebrew University Medical Center)
No relevant financial relationships

Steroid Treatment in the Management of Destructive Thyrotoxicosis Induced by PD1 Blockade
Presenter: Alessandro Brancatella, MD (Endocrinology Unit, University of Pisa, Italy)
No relevant financial relationships

Steroid Treatment in the Management of Destructive Thyrotoxicosis Induced by PD1 Blockade
Presenter: Laura Pierotti, MD (Endocrinology Unit, University of Pisa, Italy)
No relevant financial relationships

Steroid Treatment in the Management of Destructive Thyrotoxicosis Induced by PD1 Blockade
Presenter: Nicola Viola, MD (Endocrinology Unit, University of Pisa, Italy)
No relevant financial relationships

Steroid Treatment in the Management of Destructive Thyrotoxicosis Induced by PD1 Blockade
Presenter: Daniele Sgrò, MD (Endocrinology Unit, University of Pisa, Italy)
No relevant financial relationships

Steroid Treatment in the Management of Destructive Thyrotoxicosis Induced by PD1 Blockade
Presenter: Lucia Montanelli, MD (Endocrinology Unit, University of Pisa, Italy)
No relevant financial relationships

Steroid Treatment in the Management of Destructive Thyrotoxicosis Induced by PD1 Blockade
Presenter: Isabella Lupi, MD (Endocrinology Unit, University of Pisa, Italy)
No relevant financial relationships

Steroid Treatment in the Management of Destructive Thyrotoxicosis Induced by PD1 Blockade
Presenter: Chiara Sardella, MD (Endocrinology Unit, University of Pisa, Italy)
No relevant financial relationships

Steroid Treatment in the Management of Destructive Thyrotoxicosis Induced by PD1 Blockade
Presenter: Sandra Brogioni, MD (Endocrinology Unit, University of Pisa, Italy)
No relevant financial relationships

Steroid Treatment in the Management of Destructive Thyrotoxicosis Induced by PD1 Blockade
Presenter: Antonio Chella, MD (Pneumology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy)
No relevant financial relationships

Steroid Treatment in the Management of Destructive Thyrotoxicosis Induced by PD1 Blockade
Presenter: Lucia Antonangeli, MD (Endocrinology Unit, University of Pisa, Italy)
No relevant financial relationships

Steroid Treatment in the Management of Destructive Thyrotoxicosis Induced by PD1 Blockade
Presenter: Chiara Cremolini, MD (Oncology Unit, University of Pisa, Italy)
No relevant financial relationships

Steroid Treatment in the Management of Destructive Thyrotoxicosis Induced by PD1 Blockade
Presenter: Andrea Antonuzzo, MD (Oncology Unit, University of Pisa, Italy)
No relevant financial relationships

Steroid Treatment in the Management of Destructive Thyrotoxicosis Induced by PD1 Blockade
Presenter: Claudio Marcocci, MD (Endocrinology Unit, University of Pisa, Italy)
No relevant financial relationships

Steroid Treatment in the Management of Destructive Thyrotoxicosis Induced by PD1 Blockade
Presenter: Ferruccio Santini, MD (Endocrinology Unit, University of Pisa, Italy)
No relevant financial relationships

Steroid Treatment in the Management of Destructive Thyrotoxicosis Induced by PD1 Blockade
Presenter: Prof Francesco Latrofa, MD (Endocrinology Unit, University of Pisa, Italy)
No relevant financial relationships

Teprotumumab Markedly Improves Disease-related Quality of Life: Lessons From Two Randomized, Placebo-controlled Trials
Presenter: Dr. George J Kahaly, MD, PhD (Johannes Gutenberg University (JGU) Medical Center)
No relevant financial relationships

Teprotumumab Markedly Improves Disease-related Quality of Life: Lessons From Two Randomized, Placebo-controlled Trials
Presenter: Dr. Raymond S Douglas, MD, PhD (Cedars Sinai Medical Center)
No relevant financial relationships

Teprotumumab Markedly Improves Disease-related Quality of Life: Lessons From Two Randomized, Placebo-controlled Trials
Presenter: Dr. Robert Holt, PharmD, MBA (Horizon Pharma)
No relevant financial relationships

Teprotumumab Markedly Improves Disease-related Quality of Life: Lessons From Two Randomized, Placebo-controlled Trials
Presenter: Claudia Vesel, MSc (Horizon Therapeutics)
No relevant financial relationships

Teprotumumab Markedly Improves Disease-related Quality of Life: Lessons From Two Randomized, Placebo-controlled Trials
Presenter: Anahita Qashqai, MS (Horizon Therapeutics)
No relevant financial relationships

Teprotumumab Markedly Improves Disease-related Quality of Life: Lessons From Two Randomized, Placebo-controlled Trials
Presenter: Saba Sile, MD (Horizon Therapeutics)
No relevant financial relationships

Teprotumumab Markedly Improves Disease-related Quality of Life: Lessons From Two Randomized, Placebo-controlled Trials
Presenter: Terry J Smith, MD (University of Michigan)
No relevant financial relationships

Thyroglobulin Structural Requirements in Protein Trafficking for Thyroid Hormonogenesis
Presenter: Dr. Cintia Citterio, PhD (Division of Metabolism, Endocrinology & Diabetes. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA)
No relevant financial relationships

Thyroglobulin Structural Requirements in Protein Trafficking for Thyroid Hormonogenesis
Presenter: Kookjoo Kim, PhD student (Department of Physiology and Cellular Biophysics, Columbia University Irving Medical Center, NY, USA)
No relevant financial relationships

Thyroglobulin Structural Requirements in Protein Trafficking for Thyroid Hormonogenesis
Presenter: Oliver Clarke, PhD (Department of Physiology and Cellular Biophysics, Columbia University Irving Medical Center, NY, USA)
No relevant financial relationships

Thyroglobulin Structural Requirements in Protein Trafficking for Thyroid Hormonogenesis
Presenter: Peter Arvan, MD, PhD (Division of Metabolism, Endocrinology & Diabetes. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA)
No relevant financial relationships

Outcomes and Predictors of 30-day Readmission for Hyperthyroidism: A Nationwide Study
Presenter: Oluwatomi Adeoti, MD, MPH (Boston University School of Medicine/Boston Medical Center, Boston, MA, USA)
No relevant financial relationships

Outcomes and Predictors of 30-day Readmission for Hyperthyroidism: A Nationwide Study
Presenter: Michael Salim, MD (Mount Sinai Hospital, 1500 S. Fairfield, Chicago, IL, USA)
No relevant financial relationships

Outcomes and Predictors of 30-day Readmission for Hyperthyroidism: A Nationwide Study
Presenter: Asim Kichloo, MD (Central Michigan University College of Medicine, Saginaw, MI, USA)
No relevant financial relationships

Outcomes and Predictors of 30-day Readmission for Hyperthyroidism: A Nationwide Study
Presenter: Hafeez Shaka, MD (John H. Stroger Jr. Hospital Cook County, Chicago, IL, USA)
No relevant financial relationships